FDA: Anti-smoking drugs Chantix, Zyban need mental health warnings

07/1/2009 | Google

The FDA ordered warnings of mental health risks on the labels of Pfizer's Chantix and GlaxoSmithKline's Zyban in light of reports linking the smoking-cessation drugs to behavioral changes, depression, hostility and suicidal thoughts. Pfizer said it has already made the risk information available to health care providers and patients by updating Chantix's label in accordance with FDA guidelines.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ